Inotiv (NASDAQ:NOTV) Releases Quarterly Earnings Results, Misses Expectations By $0.10 EPS

Inotiv (NASDAQ:NOTV - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.10), Zacks reports. Inotiv had a negative return on equity of 15.07% and a negative net margin of 25.40%.

Inotiv Price Performance

NASDAQ NOTV traded down $0.41 during trading hours on Friday, hitting $3.51. The company's stock had a trading volume of 1,090,696 shares, compared to its average volume of 575,865. The company has a debt-to-equity ratio of 2.29, a current ratio of 1.37 and a quick ratio of 1.22. The company's 50 day simple moving average is $4.43 and its two-hundred day simple moving average is $2.82. Inotiv has a 12 month low of $1.23 and a 12 month high of $11.42.

Insider Buying and Selling at Inotiv

In other Inotiv news, COO John Gregory Beattie bought 30,000 shares of Inotiv stock in a transaction on Tuesday, December 10th. The stock was acquired at an average cost of $4.75 per share, with a total value of $142,500.00. Following the completion of the acquisition, the chief operating officer now owns 161,761 shares in the company, valued at approximately $768,364.75. This represents a 22.77 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Michael J. Harrington purchased 10,000 shares of the firm's stock in a transaction on Friday, December 6th. The shares were acquired at an average cost of $3.98 per share, for a total transaction of $39,800.00. Following the completion of the acquisition, the director now owns 37,500 shares of the company's stock, valued at approximately $149,250. This trade represents a 36.36 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 71,029 shares of company stock worth $314,248 and have sold 26,872 shares worth $112,854. Company insiders own 7.80% of the company's stock.

About Inotiv

Inotiv, Inc provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line.